MiR-20a Enhances Cisplatin Resistance of Human Gastric Cancer Cell Line by Targeting NFKBIB

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2015 Aug 20

PMID 26286834

Citations 35

Authors

Yiping Du

Mingxia Zhu

Xin Zhou

Zebo Huang

Jun Zhu

Jing Xu

Gongming Cheng

Yongqian Shu

Ping Liu

Wei Zhu

Tongshan Wang

Affiliations

Soon will be listed here.

Abstract

Drug resistance of cancer cells can be regulated by the dysregulated miRNAs, and sustained NFκB activation also plays an important role in tumor resistance to chemotherapy. Here, we sought to investigate whether there was a correlation between miR-20a and the NFκB pathway to clarify the effects that miR-20a exerted on gastric cancer (GC) chemoresistance. We found that miR-20a was significantly upregulated in GC plasma and tissue samples. In addition, it was upregulated in GC plasma and tissues from patients with cisplatin-resistant gastric cancer cell line SGC7901/cisplatin (DDP). And the upregulation of miR-20a was concurrent with the downregulation of NFKBIB (also known as IκBβ) as well as upregulation of p65, livin, and survivin. The luciferase activity suggested that NFKBIB was the direct target gene of miR-20a. Transfection of miR-20a inhibitor could increase NFKBIB level; downregulate the expression of p65, livin, and survivin; and lead to a higher proportion of apoptotic cells in SGC7901/DDP cells. Conversely, ectopic expression of miR-20a dramatically decreased the expression of NFKBIB; increased the expression of p65, livin, and survivin; and resulted in a decrease in the apoptosis induced by DDP in SGC7901 cells. Taken together, our findings suggested that miR-20a could promote activation of the NFκB pathway and downstream targets livin and survivin by targeting NFKBIB, which potentially contributed to GC chemoresistance.

Citing Articles

Dysregulation of miR-122, miR-574 and miR-375 in Egyptian patients with breast cancer.

Elghoroury E, Abdelghafar E, Kamel S, Awadallah E, Shalaby A, El-Saeed G PLoS One. 2024; 19(5):e0298536.

PMID: 38820252 PMC: 11142443. DOI: 10.1371/journal.pone.0298536.

Advances in prognostic models for osteosarcoma risk.

Yao Y, Wang D, Zheng L, Zhao J, Tan M Heliyon. 2024; 10(7):e28493.

PMID: 38586328 PMC: 10998144. DOI: 10.1016/j.heliyon.2024.e28493.

Prognostic value of plasma microRNAs for non-small cell lung cancer based on data mining models.

Yan M, Kang W, Liu X, Yang B, Sun N, Yang Y BMC Cancer. 2024; 24(1):52.

PMID: 38200421 PMC: 10777550. DOI: 10.1186/s12885-024-11830-9.

Mechanism of cisplatin resistance in gastric cancer and associated microRNAs.

Liu C, Li S, Tang Y Cancer Chemother Pharmacol. 2023; 92(5):329-340.

PMID: 37535106 DOI: 10.1007/s00280-023-04572-1.

LncRNA RUNX1-IT1 is downregulated in gastric cancer and suppresses the maturation of miR-20a by binding to its precursor.

Bao L, Du B, Guo Y, Zhang H, Mao Z Histol Histopathol. 2023; 38(11):1321-1326.

PMID: 36722424 DOI: 10.14670/HH-18-588.

References

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Sui C, Meng F, Li Y, Jiang Y . miR-148b reverses cisplatin-resistance in non-small cell cancer cells via negatively regulating DNA (cytosine-5)-methyltransferase 1(DNMT1) expression. J Transl Med. 2015; 13:132. PMC: 4417300. DOI: 10.1186/s12967-015-0488-y. View

Li X, Zhang Z, Yu M, Li L, Du G, Xiao W . Involvement of miR-20a in promoting gastric cancer progression by targeting early growth response 2 (EGR2). Int J Mol Sci. 2013; 14(8):16226-39. PMC: 3759908. DOI: 10.3390/ijms140816226. View

Michaelis M, Rothweiler F, Barth S, Cinatl J, van Rikxoort M, Loschmann N . Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells. Cell Death Dis. 2011; 2:e243. PMC: 3252738. DOI: 10.1038/cddis.2011.129. View

Shang Y, Zhang Z, Liu Z, Feng B, Ren G, Li K . miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1. Oncogene. 2013; 33(25):3267-76. DOI: 10.1038/onc.2013.297. View

Nakagawa Y, Sedukhina A, Okamoto N, Nagasawa S, Suzuki N, Ohta T . NF-κB signaling mediates acquired resistance after PARP inhibition. Oncotarget. 2015; 6(6):3825-39. PMC: 4414156. DOI: 10.18632/oncotarget.2868. View

Eberle K, Sansing H, Szaniszlo P, Resto V, Berrier A . Carcinoma matrix controls resistance to cisplatin through talin regulation of NF-kB. PLoS One. 2011; 6(6):e21496. PMC: 3123362. DOI: 10.1371/journal.pone.0021496. View

Lin X, Zhang X, Wang Q, Li J, Zhang P, Zhao M . Perifosine downregulates MDR1 gene expression and reverses multidrug-resistant phenotype by inhibiting PI3K/Akt/NF-κB signaling pathway in a human breast cancer cell line. Neoplasma. 2012; 59(3):248-56. DOI: 10.4149/neo_2012_032. View

Zhao D, Chen Y, Jiang H, Lu J, Zhang G, Geng J . Serum miR-210 and miR-30a expressions tend to revert to fetal levels in Chinese adult patients with chronic heart failure. Cardiovasc Pathol. 2013; 22(6):444-50. DOI: 10.1016/j.carpath.2013.04.001. View

10.

Zeng X, Xiang J, Wu M, Xiong W, Tang H, Deng M . Circulating miR-17, miR-20a, miR-29c, and miR-223 combined as non-invasive biomarkers in nasopharyngeal carcinoma. PLoS One. 2012; 7(10):e46367. PMC: 3466268. DOI: 10.1371/journal.pone.0046367. View

11.

Zhou R, Hu G, Gong A, Chen X . Binding of NF-kappaB p65 subunit to the promoter elements is involved in LPS-induced transactivation of miRNA genes in human biliary epithelial cells. Nucleic Acids Res. 2010; 38(10):3222-32. PMC: 2879527. DOI: 10.1093/nar/gkq056. View

12.

Zhu W, Shan X, Wang T, Shu Y, Liu P . miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer. 2010; 127(11):2520-9. DOI: 10.1002/ijc.25260. View

13.

Huang G, Nishimoto K, Zhou Z, Hughes D, Kleinerman E . miR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression. Cancer Res. 2011; 72(4):908-16. PMC: 3288434. DOI: 10.1158/0008-5472.CAN-11-1460. View

14.

Longley D, Johnston P . Molecular mechanisms of drug resistance. J Pathol. 2005; 205(2):275-92. DOI: 10.1002/path.1706. View

15.

Xia J, Chen L, Jian W, Wang K, Yang Y, He W . MicroRNA-362 induces cell proliferation and apoptosis resistance in gastric cancer by activation of NF-κB signaling. J Transl Med. 2014; 12:33. PMC: 3916099. DOI: 10.1186/1479-5876-12-33. View

16.

Holohan C, Van Schaeybroeck S, Longley D, Johnston P . Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013; 13(10):714-26. DOI: 10.1038/nrc3599. View

17.

Chai H, Liu M, Tian R, Li X, Tang H . miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines. Acta Biochim Biophys Sin (Shanghai). 2011; 43(3):217-25. DOI: 10.1093/abbs/gmq125. View

18.

van Jaarsveld M, Helleman J, Boersma A, van Kuijk P, van Ijcken W, Despierre E . miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene. 2012; 32(36):4284-93. DOI: 10.1038/onc.2012.433. View

19.

Bartel D . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-97. DOI: 10.1016/s0092-8674(04)00045-5. View

20.

Fang L, Li H, Wang L, Hu J, Jin T, Wang J . MicroRNA-17-5p promotes chemotherapeutic drug resistance and tumour metastasis of colorectal cancer by repressing PTEN expression. Oncotarget. 2014; 5(10):2974-87. PMC: 4102784. DOI: 10.18632/oncotarget.1614. View